AZD-1305(AZD-1305) - 药物靶点：L-type calcium channel x Nav1.5 x hERG_在研适应症：心房颤动_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

L-type calcium channel x Nav1.5 x hERG

作用机制

L-type calcium channel阻滞剂(L-型电压门控性钙通道家族阻滞剂)、Nav1.5阻滞剂(V型钠通道蛋白α亚基阻滞剂)、hERG阻滞剂(电压门控性钾通道蛋白亚型Kv11.1阻滞剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

AstraZeneca R&D Mölndal

Odense University Hospital

非在研机构

AstraZeneca PLC

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C22H31FN4O4

InChIKeyBLLNYXOLLAVTRF-UHFFFAOYSA-N

CAS号872045-91-5

关联

15

项与 AZD-1305 相关的临床试验

NCT00957437 / Completed临床1期

A Phase I, Randomised, Open, Single-centre Study to Evaluate the Pharmacokinetics of Different Extended-release Formulations of AZD1305 When Given as Single and Repeated Oral Doses to Healthy Male Volunteers

The purpose of this study is to evaluate the pharmacokinetics of different extended-release formulations of AZD1305 when given as single and multiple oral doses to healthy male volunteers.

开始日期2009-08-01

申办/合作机构

AstraZeneca PLC

NCT00935025 / Terminated临床1期

A Single-center, Single-blind, Randomized, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Oral Doses of AZD1305 Extended-release Capsules in Healthy Male Japanese and Caucasian Subjects

This is a phase I, single-blind, randomized, placebo-controlled single and repeated ascending dose study to assess the safety, tolerability and pharmacokinetics with oral doses of AZD1305 extended-release capsules in healthy male Japanese and Caucasian subjects. Three (or four if needed) dose levels will be given to Japanese subjects and one of the doses will also be given to Caucasian subjects.

开始日期2009-07-01

申办/合作机构

AstraZeneca PLC

EUCTR2009-009862-15-CZ / Not yet recruitingN/A

A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation

开始日期2009-06-16

申办/合作机构-

100 项与 AZD-1305 相关的临床结果

登录后查看更多信息

100 项与 AZD-1305 相关的转化医学

登录后查看更多信息

100 项与 AZD-1305 相关的专利（医药）

登录后查看更多信息

15

项与 AZD-1305 相关的文献（医药）

2017-10-01·British Journal of Pharmacology2区 · 医学

Predicting QRS and PR interval prolongations in humans using nonclinical data

2区 · 医学

Article

作者: Bergenholm, L ; Parkinson, J ; Collins, T ; Mettetal, J ; Evans, N D ; Chappell, M J

Background and PurposeRisk of cardiac conduction slowing (QRS/PR prolongations) is assessed prior to clinical trials using in vitro and in vivo studies. Understanding the quantitative translation of these studies to the clinical situation enables improved risk assessment in the nonclinical phase.Experimental ApproachFour compounds that prolong QRS and/or PR (AZD1305, flecainide, quinidine and verapamil) were characterized using in vitro (sodium/calcium channels), in vivo (guinea pigs/dogs) and clinical data. Concentration‐matched translational relationships were developed based on in vitro and in vivo modelling, and the in vitro to clinical translation of AZD1305 was quantified using an in vitro model.Key ResultsMeaningful (10%) human QRS/PR effects correlated with low levels of in vitro Nav1.5 block (3–7%) and Cav1.2 binding (13–21%) for all compounds. The in vitro model developed using AZD1305 successfully predicted QRS/PR effects for the remaining drugs. Meaningful QRS/PR changes in humans correlated with small effects in guinea pigs and dogs (QRS 2.3–4.6% and PR 2.3–10%), suggesting that worst‐case human effects can be predicted by assuming four times greater effects at the same concentration from dog/guinea pig data.Conclusion and ImplicationsSmall changes in vitro and in vivo consistently translated to meaningful PR/QRS changes in humans across compounds. Assuming broad applicability of these approaches to assess cardiovascular safety risk for non–arrhythmic drugs, this study provides a means of predicting human QRS/PR effects of new drugs from effects observed in nonclinical studies.

2016-09-01·Clinical Pharmacology in Drug Development4区 · 医学

In Silico Predictions and In Vivo Results of Drug–Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate

4区 · 医学

Article

作者: Löfberg, Boel ; Frison, Lars ; Lunde, Helen ; Edvardsson, Nils ; Cullberg, Marie ; Aunes, Maria ; Johansson, Susanne

AbstractThe objectives were to estimate and compare, in silico and in vivo, the effects of a strong and a moderate CYP3A4 inhibitor on AZD1305 pharmacokinetics. In silico, simulations were performed with the computer software Simcyp, and the predicted outcome was compared with the results observed in healthy male subjects. In silico, the geometric mean plasma exposure of AZD1305 + ketoconazole showed a 7.1‐fold higher AUC and a 4.4‐fold higher Cmax compared with AZD1305 alone. Coadministration with verapamil gave a 1.9‐fold higher AUC and a 1.7‐fold higher Cmax compared with AZD1305 alone. In vivo, the plasma exposure of AZD1305 + ketoconazole showed a 7.7‐fold higher AUC and a 4.8 ‐fold higher Cmax compared with AZD1305 alone. Coadministration with verapamil gave a 2.2‐fold higher AUC and a 2.0‐fold higher Cmax compared with AZD1305 alone. The mean maximum QTcF increase from baseline was 407, 487, and 437 milliseconds for AZD1305, alone and in combination with verapamil or ketoconazole, respectively. Simcyp predicted the effects of ketoconazole and verapamil on the sensitive CYP3A4 substrate AZD1305 pharmacokinetics well. Both the in vivo study and the Simcyp predictions suggest a contraindication for strong CYP3A4 inhibitors and AZD1305 when given in combination.

2016-05-01·Journal of Pharmacological and Toxicological Methods4区 · 医学

PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data

4区 · 医学

Article

作者: Parkinson, Joanna ; Collins, Teresa ; Bergenholm, Linnéa ; Chappell, Michael J ; Evans, Neil D

INTRODUCTIONPharmacokinetic-pharmacodynamic (PKPD) modelling can improve safety assessment, but few PKPD models describing drug-induced QRS and PR prolongations have been published. This investigation aims to develop and evaluate PKPD models for describing QRS and PR effects in routine safety studies.METHODSExposure and telemetry data from safety pharmacology studies in conscious beagle dogs were acquired. Mixed effects baseline and PK-QRS/PR models were developed for the anti-arrhythmic compounds AZD1305, flecainide, quinidine and verapamil and the anti-muscarinic compounds AZD8683 and AZD9164. RR interval correction and circadian rhythms were investigated for predicting baseline variability. Individual PK predictions were used to drive the pharmacological effects evaluating linear and non-linear direct and effect compartment models.RESULTSConduction slowing induced by the tested anti-arrhythmics was direct and proportional at low exposures, whilst time delays and non-linear effects were evident for the tested anti-muscarinics. AZD1305, flecainide and quinidine induced QRS widening with 4.2, 10 and 5.6% μM(-1) unbound drug. AZD1305 and flecainide also prolonged PR with 13.5 and 11.5% μM(-1). PR prolongations induced by the anti-muscarinics and verapamil were best described by Emax models with maximal effects ranging from 55 to 95%. RR interval correction and circadian rhythm improved PR but not QRS modelling. However, circadian rhythm had minor impact on estimated drug effects.DISCUSSIONBaseline and drug-induced effects on QRS and PR intervals can be effectively described with PKPD models using routine data, providing quantitative safety information to support drug discovery and development.

100 项与 AZD-1305 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	AZD-1305	-	DB11766

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
左心室功能不全	临床2期	瑞典	AstraZeneca PLC	2008-08-01
心房颤动	临床2期	俄罗斯	AstraZeneca PLC	2008-03-01
心房颤动	临床2期	挪威	AstraZeneca PLC	2008-03-01
心房颤动	临床2期	斯洛伐克	AstraZeneca PLC	2008-03-01
心房颤动	临床2期	波兰	AstraZeneca PLC	2008-03-01
心房颤动	临床2期	丹麦	AstraZeneca PLC	2008-03-01
心房扑动	临床2期	瑞典	AstraZeneca PLC	2008-01-01
心房扑动	临床2期	挪威	AstraZeneca PLC	2008-01-01
心房扑动	临床2期	芬兰	AstraZeneca PLC	2008-01-01
心房扑动	临床2期	丹麦	AstraZeneca PLC	2008-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00915356 (CTgov)	临床2期	心房颤动	228	AZD1305 (AZD1305 Dose Group 1)	鬱窪餘膚鹽醖獵獵獵顧(窪鏇衊淵製鹹窪艱廠齋) = 觸鹹齋鹹願遞積顧憲積觸鏇鏇繭遞膚觸範膚夢 (糧糧積夢膚製願獵網醖, 襯願廠鹽網遞窪構繭願 ~ 築醖製淵觸鏇壓鹹鹽選) 更多	-	2012-02-01
				AZD1305 (AZD1305 Dose Group 2)	鬱窪餘膚鹽醖獵獵獵顧(窪鏇衊淵製鹹窪艱廠齋) = 壓鏇遞願築艱壓衊選窪觸鏇鏇繭遞膚觸範膚夢 (糧糧積夢膚製願獵網醖, 齋選衊獵齋餘鏇獵構範 ~ 鏇夢膚鏇艱窪觸鬱網壓) 更多
NCT00643448 (CTgov)	临床2期	心房颤动	65	AZD1305 (AZD1305 Group A and AZD1305 Group B)	糧衊鑰壓餘憲廠憲艱積(醖鑰製蓋膚憲鹽艱繭網) = 衊獵鑰窪築選願鑰積選繭鹽積艱衊蓋選網餘淵 (繭鬱糧窪獵積獵構餘鹽, 鏇鹽鹽鏇範壓糧繭窪觸 ~ 獵願憲艱艱餘糧餘廠範) 更多	-	2012-01-26
				Placebo+AZD1305 (Placebo)	糧衊鑰壓餘憲廠憲艱積(醖鑰製蓋膚憲鹽艱繭網) = 鏇獵醖餘鑰願構獵夢蓋繭鹽積艱衊蓋選網餘淵 (繭鬱糧窪獵積獵構餘鹽, 繭選顧範齋壓餘選襯膚 ~ 淵壓鑰餘鏇鹽蓋製憲積) 更多
NCT00915356 (Pubmed \| Europace)	临床2期	心房颤动	171	AZD1305	窪壓顧獵鑰鬱繭願糧鹽(積觸簾廠選窪鑰鏇鏇鹹) = 願醖窪繭鏇獵醖網範壓鬱鏇廠選衊夢夢蓋顧餘 (範夢壓顧製蓋範構廠鏇 ) 更多	不佳	2011-08-01
NCT00748982 (CTgov)	临床2期	左心室功能不全	16	AZD1305 (AZD1305 Dose 1 and Dose 2)	觸鹹簾夢選鏇網繭獵願(鹽鹹製艱繭製廠簾齋鹹) = 網鏇構鹽憲選鑰壓觸衊衊醖築鏇網醖艱願鹹餘 (膚積選窪蓋窪淵鏇窪糧, 願繭獵顧觸鹽顧鹽艱廠 ~ 糧廠艱壓壓鏇觸顧積糧) 更多	-	2011-06-13
				Placebo (Placebo Dose 1 and Dose 2)	觸鹹簾夢選鏇網繭獵願(鹽鹹製艱繭製廠簾齋鹹) = 觸鏇鑰鏇繭積鬱鏇選壓衊醖築鏇網醖艱願鹹餘 (膚積選窪蓋窪淵鏇窪糧, 積遞餘襯衊願簾鬱獵齋 ~ 網獵鏇壓淵壓製遞壓鏇) 更多